• Invivyd launched FLINTLOCK, a Phase 2 trial of VYD2311 for Long COVID or post-vaccination syndrome.
• Safety and potential clinical benefit will be assessed versus placebo over 90 days in adults aged 18-65.
• Initial readout is expected in mid-2027; no results have been presented yet.
• Program expands VYD2311’s development beyond prevention, targeting a large unmet-need population with limited treatment options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140701PRIMZONEFULLFEED9845254) on October 14, 2026, and is solely responsible for the information contained therein.